Treatment of glomerulonephritis: will we ever have options other than steroids and cytotoxics?
Glomerulonephritis refers to a collection of primary renal disorders and those secondary to a systemic disease, all characterized by inflammation within the glomerulus. Given the underlying immunologic nature of these disorders, they are routinely treated with corticosteriods and various cytotoxic agents. Although in many instances such therapies are successful, they are associated with significant morbidity; as such, alternatives are clearly necessary. Our understanding of the pathogenesis of immunologic glomerular diseases has grown remarkably, in large part from the study of rodent disease models. Fundamental to each disorder is the development of an antigen-specific immune response followed by the effector stage of inflammation. To block the immune response, antigen-specific therapy can be used to induce tolerance, such as through the use of double-stranded DNA molecules in lupus nephritis. Since other antigen systems are less well characterized, inducing a more generalized impairment in the immune response by blocking costimulatory molecules CD40-CD154 and CD28-CD80/86 is a growing approach to treat various immunologic disorders and transplantation. To reduce glomerular inflammation, a variety of effector systems have been targeted, including complement, cytokines/chemokines, adhesion molecules, and mediators of cellular proliferation. Of these, antibodies targeting C5 in the complement system, and antibody and receptor antagonists of tumor necrosis factor-alpha (TNF-alpha) have already been used in glomerular disorders with some promise. Less specific blockade of receptor-mediated events stimulated by platelet-derived growth factors and cell cycle proteins may soon be applied to glomerulonephritis. Finally, interruption of fibrosing pathways, which lead to glomerulosclerosis and interstitial fibrosis common to the end-stage of all glomerulonephritis, is the subject of intense effort which may yield effective biologic therapies. In spite of all these advances, we still are dependent on steroids and cytotoxics to treat glomerulonephritis. To get past this, we must devote significant resources to take observations made in basic research laboratories to develop therapeutics and prove their utility in human disease.
Javaid
Basit
B
Section of Nephrology, The University of Chicago, Chicago, Illinois 60637, USA.
Quigg
Richard J
RJ
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000936:Antigen-Antibody Complex / Q000187:drug effects; D000941:Antigens / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors; D049109:Cell Proliferation / Q000187:drug effects; D018925:Chemokines / Q000037:antagonists & inhibitors; D003167:Complement Activation / Q000187:drug effects; D016207:Cytokines / Q000037:antagonists & inhibitors; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000209:etiology / Q000266:history / Q000276:immunology; D049673:History, 20th Century; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008213:Lymphocyte Activation / Q000187:drug effects
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000936:Antigen-Antibody Complex; D000941:Antigens; D000970:Antineoplastic Agents; D015815:Cell Adhesion Molecules; D018925:Chemokines; D016207:Cytokines; D007166:Immunosuppressive Agents